paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
paridiprubart (EB07) / Edesa Biotech, Light Chain Biosci
2020-006044-14: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EB05 + standard of care versus placebo + standard of care in adult hospitalized patients with COVID19

Not yet recruiting
3
1501
Europe
EB05, Solution for infusion
Edesa Biotech Research Inc., Edesa Biotech Research Inc.
SARS-CoV-2 Positive Pneumonia - level 3-7 in the nine-point COVID-19 severity scale:, SARS-CoV-2 Positive Pneumonia, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT04401475: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19

Suspended
2/3
644
Canada, US
SOC plus 15mg/kg EB05 IV, SOC plus Placebo IV
Edesa Biotech Inc., JSS Medical Research Inc.
COVID-19, ARDS
12/24
12/24

Download Options